Tuesday, September 30, 2008
News - Lymphadenectomy Improves 5-Year Survival Rates in Ovarian Cancer Patients: Presented at ESSO
Note the year of 1986:
News - Lymphadenectomy Improves 5-Year Survival Rates in Ovarian Cancer Patients: Presented at ESSO: "The International Federation of Gynaecology and Obstetrics (FIGO) staging for ovarian cancer changed in 1986 to include both peritoneal and lymphatic assessment, Dr. Bergzoll noted."
Friday, September 26, 2008
Thursday, September 25, 2008
Wednesday, September 24, 2008
Cochrane Systematic Review of Colorectal Cancer Screening
Cochrane Systematic Review of Colorectal Cancer Screening
"Conclusions:
........Controversy still surrounds the most effective screening modality for the detection of CRC in the population.[9–11] Clarification of whether FOBT (either guaiac or immunochemical), flexible sigmoidoscopy (alone or in combination with FOBT), or colonoscopy will provide the greatest benefits over the potential risks is required."
Tuesday, September 23, 2008
Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer
Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer -- Hampel et al., 10.1200/JCO.2008.17.5950 -- Journal of Clinical Oncology
Conclusion:
One of every 35 patients with CRC has LS, and each has at least three relatives with LS; all of whom can benefit from increased cancer surveillance. For screening, IHC is almost equally sensitive as MSI, but IHC is more readily available and helps to direct gene testing. Limiting tumor analysis to patients who fulfill Bethesda criteria would fail to identify 28% (or one in four) cases of LS.
Monday, September 22, 2008
full text (news source) What is the role of neoadjuvant chemo - areas of confusion in oncology
PowerSearch Document
"RECOMMENDATIONS
* Patients unable to tolerate aggressive cytoreductive surgery should undergo neoadjuvant chemotherapy first.
* Neoadjuvant chemotherapy should become a standard alternative approach to treating patients with stage IV ovarian cancer.
* Women with stage IIIC disease should be evaluated by a gynecologic oncologist to determine the likelihood of optimal cytoreducibility. If residual macroscopic disease would be expected with surgery alone, the patient should be offered the option of neoadjuvant chemotherapy."
Reference Guide
Therapeutic Agents Mentioned in This Article
Carboplatin
Cisplatin
Cyclophosphamide
Paclitaxel
Sunday, September 21, 2008
Friday, September 19, 2008
Thursday, September 18, 2008
2008 Canada Health Consumer Index
47. 2008Sept CHCI Final.pdf (application/pdf Object)
No province in Canada has legislation defending the rights of patients.
Wednesday, September 17, 2008
Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer
Modification of risk for subsequent cancer after f...[Breast Cancer Res Treat. 2008] - PubMed Result
- Breast Cancer Res Treat. 2008 Sep;111(1):165-9. Epub 2007 Sep 27.
-
Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer.
Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. k.hemminki@dkfz.de
An increased risk of second primary cancers may depend on many reasons, including therapy for the first cancer and heritable causation. Population level data are not available exploring the risks of subsequent cancers after breast cancer considering a familial history of breast cancers. We used the nation-wide Swedish Family-Cancer Database to investigate such risks, based on 43,398 first invasive female breast cancers. Standardized incidence ratios (SIRs) were calculated for the second cancer after breast cancer using rates for first cancer as a reference. Many cancers at discordant sites were increased after breast cancer. SIRs for subsequent neoplasms in women who had a family history of breast cancer were increased for ovarian (2.0) and endometrial (1.8) cancers and for acute lymphoid leukemia (12.7) and myelofibrosis (9.4). The data suggest that the familial aggregation of breast and endometrial cancers may be explained by yet unidentified heritable causes. The remarkably high risks for second acute lymphoid leukemia and myelofibrosis, both characterized by chromosomal aberrations, in women with a family history of breast cancer may signal heritable defects in the ability to process DNA damage caused by ionizing radiation and chemotherapy.
Tuesday, September 16, 2008
Lymphadenectomy Improves 5-Year Survival Rates in Ovarian Cancer Patients: Presented at ESSO
"Since there might be some overlap between performing radical surgery and performing lymphadenectomy, maximal cytoreduction should remain the main objective in ovarian cancer surgery," Dr. Bergzoll concluded.
[Presentation title: The Therapeutic Role of Lymph Node Resection in Ovarian Cancer: Analysis of the Surveillance, Epidemiology, and End Results Database. Abstract 152]
2008 OCNA award winners: Carolyn Benivegna and Karen Mason
OCNA 2008 Award Winners! CONGRATULATIONS!
Cindy Melancon Spirit of Survivorship AwardHailing from Novi, Michigan, Carolyn Benivegna will be this year’s recipient in honor of her persistent advocacy for promoting awareness for ovarian cancer. Carolyn is an ovarian cancer survivor and the founder of the Ovarian Cancer Alliance of Florida-Gulf Coast. She then moved to Michigan when she made a great impact by working with Governor Jennifer Granholm to declare September as Ovarian Cancer Awareness Month. Carolyn and her husband were also recognized by The Henry P. Tappan Society from the University of Michigan for establishing an endowed Ovarian Cancer Research Fund at UM.
The Voice for Ovarian Cancer Research Award
Taking the trip from Woodbury, NJ will be Karen Mason. After being diagnosed at the age of 49, she quickly discovered that getting involved in the ovarian cancer community was a great coping mechanism. Last Fall Karen was invited to be a member of the Dept of Defense’s Integration Panel where proposals are chosen for funding by the Department of Defense’s Ovarian Cancer Research Program. She also serves as a patient advocate for the Fox Chase Cancer Center ovarian SPORE as a full participating member of their Institutional Review Board evaluating consent forms for clinical trials. Karen is continually involved with NED (no evidence of disease) and is a part-time ICU nurse, wife and mother of two sons.
JCO.2008 Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception
Progress in Cancer Care: The Hope,JCO.2008.17.6198v1.pdf (application/pdf Object)
the Hype, and the Gap Between Reality
and Perception
abstract:
JCO Early Release, published online ahead of print Sep 15 2008
Journal of Clinical Oncology, 10.1200/JCO.2008.17.6198
| |
Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception
Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY
Subscribe to:
Posts
(
Atom
)
